Souhaitez-vous accéder aux communiqués récents ?

DALLAS, Dec. 30, 2024 (GLOBE NEWSWIRE) -- The 2024 Rising Stars of the life sciences and healthcare innovation sector took center stage at the iC³ Life Science Summit this year, marking another...

CBIH has formally filed a petition to have Ms. Alexis Bortell serve as a witness in the upcoming DEA hearing on marijuana rescheduling.

Cannabis Bioscience International Holdings CEO Dante Picazo Addresses Cannabis Reclassification and DEA Hearings

Elevai Labs Inc. Subsidiary, Elevai Skincare, Launches S-Series Root Renewal System, Marking Entry into Hair Care Market

our Research and Development team is redefining the possibilities of cannabinoid-based biotechnologies and at the heart of these innovations lies the Rejuv

/CORRECTION/ Elevai Labs Inc. Reports Financial Results for the Third Fiscal Quarter of 2024 and Provides Business Update

Dublin, Nov. 14, 2024 (GLOBE NEWSWIRE) -- The "Bone Metabolism Assays Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2024 Update"...

Elevai Biosciences Engages Leading CRO to Support Regulatory Planning Efforts and Pre-IND Meeting with the FDA for EL-22 For The Treatment of Obesity

Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Highlights Past Positive Preclinical Data Showing Potential of EL-32, A Dual Myostatin & Activin-A Bl

Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Expands Patent Portfolio with Two New Filings for EL-22 in Muscle Loss Treatment for Obese Patients,